O’Melveny & Myers LLP advised Urovant Sciences on the deal. Urovant Sciences announced its US$681 million definitive merger agreement with Sumitovant Biopharma. According to the terms…
This content is for Standard 1 Year members only. LoginJoin Now
Author: Ambrogio Visconti
…
This content is for Standard 1 Year members only. LoginJoin Now